{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=40", "query": { "condition": "Advanced Solid Neoplasm", "page": 40 }, "page_size": 10 }, "pagination": { "page": 40, "page_size": 10, "total_count": 3387, "total_pages": 339, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=41&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Neoplasm&page=39&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-13T07:17:54.824Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05269316", "title": "Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "IMP9064", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Impact Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 61, "start_date": "2022-02-11", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-04-01", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 4, "location_summary": "Hackensack, New Jersey • New York, New York • Greenville, South Carolina + 1 more", "locations": [ { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Greenville", "state": "South Carolina" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05269316" }, { "nct_id": "NCT02214147", "title": "Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Relapsed/Refractory Lymphoma" ], "interventions": [ { "name": "Alisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2014-08-21", "completion_date": "2016-07-18", "has_results": true, "last_update_posted_date": "2018-11-15", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 7, "location_summary": "Miami, Florida • Chicago, Illinois • Ann Arbor, Michigan + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02214147" }, { "nct_id": "NCT03946800", "title": "A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors", "Cancer" ], "interventions": [ { "name": "MEDI1191", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "101 Years", "sex": "ALL", "summary": "18 Years to 101 Years" }, "enrollment_count": 61, "start_date": "2019-05-08", "completion_date": "2023-08-24", "has_results": false, "last_update_posted_date": "2024-10-02", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 8, "location_summary": "La Jolla, California • Los Angeles, California • New York, New York + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03946800" }, { "nct_id": "NCT01300533", "title": "A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Cancer", "Cancer", "Solid Tumors" ], "interventions": [ { "name": "BIND-014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BIND Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-01", "completion_date": "2016-02", "has_results": false, "last_update_posted_date": "2016-02-09", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 6, "location_summary": "Scottsdale, Arizona • Greenbrae, California • Los Angeles, California + 3 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Fort Meyers", "state": "Florida" }, { "city": "Detriot", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01300533" }, { "nct_id": "NCT06942104", "title": "Imaging of Solid Tumors Using 18F-TRX", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Solid Carcinoma", "Castration-Resistant Prostate Carcinoma", "Locally Advanced Clear Cell Renal Cell Carcinoma", "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Glioma, Malignant" ], "interventions": [ { "name": "18F-TRX", "type": "DRUG" }, { "name": "Positron Emission Tomography (PET)/Computerized tomography (CT)", "type": "PROCEDURE" }, { "name": "Tumor Biopsy", "type": "PROCEDURE" }, { "name": "Blood Specimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Rahul Aggarwal", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2025-07-03", "completion_date": "2027-09-30", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06942104" }, { "nct_id": "NCT06160752", "title": "Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Cholangiocarcinoma", "Intrahepatic Cholangiocarcinoma", "Solid Tumor", "Metastatic Cholangiocarcinoma" ], "interventions": [ { "name": "Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" }, { "name": "Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2023-11-22", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Columbus, Ohio + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06160752" }, { "nct_id": "NCT07814248", "title": "A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NSCLC (Non-small Cell Lung Cancer)", "HNSCC", "Endometrial", "Ovarian Cancer", "Esophageal Cancer", "Head & Neck Cancer", "Gastric Cancer (GC)", "Endometrial Cancer" ], "interventions": [ { "name": "TS-104", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TwoStep Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2026-09-02", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 3, "location_summary": "Maumee, Ohio • Portland, Oregon • Fairfax, Virginia", "locations": [ { "city": "Maumee", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07814248" }, { "nct_id": "NCT03386721", "title": "Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced/Metastatic Head and Neck, Oesophageal and Cervical Cancers" ], "interventions": [ { "name": "simlukafusp alfa", "type": "DRUG" }, { "name": "Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2018-02-19", "completion_date": "2021-12-30", "has_results": true, "last_update_posted_date": "2023-02-21", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 2, "location_summary": "San Francisco, California • Newnan, Georgia", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03386721" }, { "nct_id": "NCT07266285", "title": "BTM-3566 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BTM-3566", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bantam Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2025-12-10", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2025-12-17", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 2, "location_summary": "Houston, Texas • San Antonio, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07266285" }, { "nct_id": "NCT04752215", "title": "A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell Surface", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Carcinoma, Hepatocellular, Head and Neck Neoplasms, Gastrointestinal Neoplasms" ], "interventions": [ { "name": "BI 765049", "type": "DRUG" }, { "name": "ezabenlimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2021-05-18", "completion_date": "2024-12-17", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-11-13T07:17:54.824Z", "location_count": 13, "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04752215" } ] }